The National Institute for Health and Care Excellence (NICE) has recommended cemiplimab for treating advanced cervical cancer in eligible patients in the UK. This decision follows a thorough evaluation of the treatment's effectiveness and cost-effectiveness. According to NICE, cemiplimab has been shown to improve overall survival rates and response rates in patients with advanced cervical cancer.
Advanced cervical cancer is a serious condition, accounting for around 8% of all cervical cancer cases in the UK. While the incidence of cervical cancer has decreased significantly in recent years due to the introduction of the human papillomavirus (HPV) vaccine, it remains a major concern for public health. As of 2022, there were approximately 1,900 new cases of cervical cancer diagnosed in the UK each year.
The NICE recommendation is based on clinical trial data showing that cemiplimab significantly improves outcomes for patients with advanced cervical cancer. In the phase 3 trial, patients treated with cemiplimab had a higher overall response rate (35.4%) and a longer median overall survival (8.8 months) compared to those receiving chemotherapy alone.
While cemiplimab offers new hope for patients with advanced cervical cancer, it's essential to note that this treatment is not suitable for everyone. NICE will specify the eligibility criteria in their guidance, which will be based on factors such as the stage of the disease, the patient's overall health, and any underlying medical conditions.
In the UK, approximately 5,300 women are diagnosed with cervical cancer each year, and around 970 women die from the disease annually. The NICE recommendation of cemiplimab is expected to improve treatment options for thousands of women with advanced cervical cancer in the UK.